Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
复制标题
DOI：
10.3201/eid2607.200841
复制
发表时间：
2020-07-01
影响因子：
11.8
通讯作者：
Haagmans, Bart L.
中科院分区：
文献类型：
--
作者：
Okba, Nisreen M. A.;Mueller, Marcel A.;Haagmans, Bart L.
最近出现了一种新的冠状病毒，即严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)，可引起人间大流行。虽然分子诊断测试迅速发展，血清学分析仍然缺乏，但迫切需要。在接触者追踪、确定病毒库和流行病学研究中需要经过验证的血清学分析。我们开发了检测SARS-CoV-2中和抗体、刺突蛋白特异性抗体和核衣壳特异性抗体的血清学检测方法。使用pcr确诊的SARS-CoV-2感染、其他冠状病毒或其他呼吸道致病性感染患者的血清样本，我们在不同的内部和商业elisa中验证和测试了各种抗原。我们证明，大多数pcr确诊的sars - cov -2感染者在发病后2周内血清转化。我们发现市售的S1 IgG或IgA elisa特异性较低，两种检测方法的敏感性不同；IgA ELISA检测结果敏感性较高。总的来说，所描述的经过验证的检测方法可用于检测sars - cov -2特异性抗体，用于诊断、血清流行病学和疫苗评估研究。
A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.